
浏览全部资源
扫码关注微信
1.河北省中医院,石家庄 050007
2.河北省井陉县中医院,石家庄 050300
李普阳,硕士,主治医师,从事神经疾病的临床工作,E-mail:monkeypeople@163.com
付增彬,副主任医师,从事脑肿瘤疾病的临床工作,E-mail:fuzb123@163.com
收稿日期:2020-10-15,
网络出版日期:2021-03-01,
纸质出版日期:2021-09-05
移动端阅览
李普阳,付增彬,李月牛等.血速升颗粒对癌因性疲乏患者的疗效评价及机制[J].中国实验方剂学杂志,2021,27(17):118-123.
LI Pu-yang,FU Zeng-bin,LI Yue-niu,et al.Clinical Evaluation and Mechanism of Xuesusheng Granule for Patients with Cancer Related Fatigue[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(17):118-123.
李普阳,付增彬,李月牛等.血速升颗粒对癌因性疲乏患者的疗效评价及机制[J].中国实验方剂学杂志,2021,27(17):118-123. DOI: 10.13422/j.cnki.syfjx.20210632.
LI Pu-yang,FU Zeng-bin,LI Yue-niu,et al.Clinical Evaluation and Mechanism of Xuesusheng Granule for Patients with Cancer Related Fatigue[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(17):118-123. DOI: 10.13422/j.cnki.syfjx.20210632.
目的
2
评价血速升颗粒对癌因性疲乏(CRF)气血两虚证患者免疫功能、生活质量的影响。
方法
2
按随机数字表法,将118例患者分为对照组和观察组各59例。对照组口服阿胶黄芪口服液,10~20 mL/次,2次/d;观察组口服血速升颗粒,10 g/次,3次/d。两组疗程均为8周。进行治疗前后癌症疲乏量表(CFS),癌症治疗功能评价量表(FACT)和气血两虚证评分,采用简易疲乏量表(BFI-C)评价治疗前后疲乏程度;比较治疗前后外周血白细胞计数(WBC),中性粒细胞计数(NEU),血小板计数(PLT),红细胞计数(RBC)和血红蛋白(Hb)水平;检测治疗前后T淋巴细胞亚群(CD3
+
,CD4
+
,CD8
+
),自然杀伤细胞(NK),白细胞介素-1(IL-1),IL-6,IL-8和肿瘤坏死因子-
α
(TNF-
α
)水平;进行安全性评价。
结果
2
治疗后,观察组CFS量表各因子评分及CFS总分均低于对照组(
P
<
0.01);观察组的疲乏程度低于对照组(
Z
=2.101,
P
<
0.05);观察组FACT总分及生理、社会/家庭、情绪和功能4个维度评分均低于对照组(
P
<
0.01);观察组WBC,NEU,RBC和Hb水平均高于对照组(
P
<
0.01);观察组BFI-C评分和气血两虚证评分均低于对照组(
P
<
0.01);观察组NK,CD3
+
,CD4
+
水平和CD4
+
/CD8
+
水平均高于对照组(
P
<
0.01),观察组IL-1,CD8
+
,IL-6,IL-8和TNF-
α
水平均低于对照组(
P
<
0.01)。未观察到与服用血速升颗粒的相关不良反应。
结论
2
血速升颗粒治疗CRF气血两虚证患者,可减轻疲乏症状和疲乏程度,提高患者的生活质量,并可减轻骨髓的抑制程度,提高免疫功能,调节免疫炎症因子,具有较好的临床疗效。
Objective
2
To discuss the clinical efficacy of Xuesusheng granule for cancer related fatigue (CRF) deficiency of both Qi and blood in clinical practice, and to investigate its effect on immune function and quality of life.
Method
2
According to random number table method, 118 patients were divided into observation group (59 cases) and control group (59 cases). Patients in control group got Ejiao Huangqi oral liquid, 10-20 mL/time, 2 times/day. Patients in observation group got Xuesusheng granule, 10 g/time, 3 times/day. The treatment was continued for 8 weeks in both groups. Before and after treatment, scores of cancer fatigue scale (CFS), functional assessment of cancer therapy (FACT) and Qi and blood deficiency syndrome were graded, and degree of fatigue was discussed with brief fatigue inventory scale-Chinese (BFI-C). Levels of white blood cell count (WBC), neutrophil count (NEU), platelet count (PLT), red blood cell count (RBC), and hemoglobin (Hb) were compared before and after treatment.T lymphocyte subsets of (CD3
+
, CD4
+
, CD8
+
) levels, natural killer (NK) cells, interleukin-1(IL-1), IL-6, IL-8 and tumor necrosis factor -
α
(TNF -
α
) were also detected, and the safety was evaluated.
Result
2
After treatment the scores of each factor in CFS scale and the total score of CFS in the observation group were lower than those in the control group (
P
<
0.01), and the degree of fatigue was lower than that in control group (
Z
=2.101,
P
<
0.05). The total score of FACT and the scores of four dimensions of physiology, society/family, emotion and function in the observation group were lower than those in the control group (
P
<
0.01). Levels of WBC, NEU, RBC and Hb in the observation group were higher than those in the control group (
P
<
0.01). Scores of BFI-C, deficiency of Qi and blood
were lower than those in control group (
P
<
0.01). Levels of NK, CD3
+
, CD4
+
and CD4
+
/CD8
+
in the observation group were all higher than those in the control group (
P
<
0.01), while the IL-1, CD8
+
, IL-6, IL-8 and TNF-
α
levels in observation group were lower than those in the control group (
P
<
0.01). Not observed, there was no adverse reaction related to Xususheng granule.
Conclusion
2
Xuesusheng granule can improve the symptoms of fatigue, reduce the degree of fatigue, improve the quality of life, reduce the degree of bone marrow suppression, improve immune function, and regulate immune inflammatory factors with high clinical efficacy in the use for patients with CRF and deficiency of Qi and blood.
吴人杰 , 谢长生 . 癌因性疲乏发病机制及治疗的研究进展 [J]. 肿瘤学杂志 , 2020 , 26 ( 3 ): 240 - 244 ..
SENGUPTA R , HONEY K . AACR Cancer Progress Report 2019: transforming lives through innovative cancer science [J]. Clin Cancer Res , 2019 , 25 ( 18 ): 5431 .
贾梦冉 , 王婧 , 李潇 , 等 . 癌因性疲乏研究现状及中医药治疗现状述评 [J]. 现代中西医结合杂志 , 2020 , 29 ( 21 ): 2390 - 2394 .
高春林 , 戴小军 . 张晓春治疗癌因性疲乏经验 [J]. 中医学报 , 2019 , 34 ( 3 ): 517 - 520 .
颜悦 , 于晓宇 , 郭姗琦 , 等 . 中医药治疗癌因性疲乏研究进展 [J]. 天津中医药 , 2019 , 36 ( 1 ): 96 - 100 .
刘力强 . 血速升颗粒治疗高分级脑胶质瘤术后放化疗患者疗效观察 [J]. 世界中医药 , 2020 , 15 ( 3 ): 430 - 433 .
牛韧 . 血速升颗粒治疗肿瘤相关性贫血的临床疗效观察 [J]. 医学理论与实践 , 2019 , 32 ( 7 ): 953 - 955 .
田艳花 , 胡宁 , 李力 , 等 . 血速升颗粒对肺癌化疗患者血液及相关免疫功能指标的影响 [J]. 肿瘤药学 , 2019 , 9 ( 3 ): 490 - 493,498 .
WANG X S , HAO X S , WANG Y , et al . Validation study of the Chinese version of the brief fatigue inventory (BFI-C) [J]. J Pain Symptom Manage , 2004 , 27 ( 4 ): 322 - 332 .
中华人民共和国卫生部 . 中国常见恶性肿瘤诊治规范 [M]. 北京 : 北京医科大学、中国协和医科大学联合出版社 , 1991 .
PORTENOY R K , ITRI L M . Cancer-related fatigue: guidelines for evaluation and management [J]. Oncologist , 1999 , 4 ( 1 ): 1 - 10 .
郑筱茰 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 378 - 380 .
张凤玲 , 丁玥 , 韩丽沙 . 癌症疲乏量表中文版的信效度 [J]. 中国心理卫生杂志 , 2011 , 25 ( 11 ): 810 - 813 .
KAISER K , BEAUMONT J L , WEBSTER K , et al . Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale [J]. Cancer Med , 2015 , 4 ( 5 ): 690 - 698 .
卿鹏 , 赵建夫 , 赵仓焕 , 等 . 针刺干预癌症相关性疲劳及对患者血清CRP,IL-6,TNF- α 及s TNF-R1水平的影响 [J]. 中国针灸 , 2020 , 40 ( 5 ): 505 - 509 .
陶子豪 , 蒋益兰 , 宋程 , 等 . 蒋益兰治疗癌因性疲乏经验 [J]. 湖南中医杂志 , 2019 , 35 ( 5 ): 27 - 28 .
吴娇 , 王聪 . 黄芪的化学成分及药理作用研究进展 [J]. 新乡医学院学报 , 2018 , 35 ( 9 ): 755 - 760 .
董晴 , 陈明苍 . 当归化学成分及药理作用研究进展 [J]. 亚太传统医药 , 2016 , 12 ( 2 ): 32 - 34 .
吴海燕 , 孙佳明 , 张辉 . 阿胶的研究进展 [J]. 吉林中医药 , 2016 , 36 ( 1 ): 57 - 60 .
罗则华 , 杜倩 , 奚鑫 , 等 . 基于网络药理学的淫羊藿抗疲劳作用机制研究 [J]. 中草药 , 2020 , 51 ( 11 ): 2997 - 3004 .
谭静 , 林红强 , 王涵 , 等 . 鸡血藤的药理作用及临床应用研究进展 [J]. 中药与临床 , 2018 , 9 ( 5 ): 61 - 65 .
米法剑 , 耿刚 . 中医药治疗调节癌因性疲乏患者免疫功能研究进展 [J]. 中国民族民间医药 , 2020 , 29 ( 9 ): 62 - 65 .
0
浏览量
23
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621